US biotech firm NiKang Therapeutics raises $200m in Series C round

US biotech firm NiKang Therapeutics raises $200m in Series C round

Photo: Pixabay

NiKang Therapeutics, a US-headquartered early-stage biotech company specialising in small molecule oncology medicines, has raised $200 million in an oversubscribed round of funding, per an announcement.